Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

Bluebird bio Inc ( (BLUE) ) has released its Q3 earnings. Here is a breakdown of the information Bluebird bio Inc presented to its investors.

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

Bluebird Bio (BLUE) Company Description: bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and ...

Welcome to bluebird bio's third quarter 2024 results conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

Research analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE – Get Free Report) in a research ...

Find out what is driving the slowdown in gene therapy investment, as the sector continues to struggle with widespread layoffs ...

It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular NHS use in first draft guidance.

Europe's market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to ...

REGENXBIO Inc. today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II ...

Two comparable companies are possible futures, namely: Crisper Therapeutics (CRSP) and Bluebird Bio (BLUE). Crisper has a ...